Recent advancements in protein engineering, especially antibody-drug conjugates, show promise in lung cancer treatment, with ...

The rally in SMMT stock is driven by encouraging updates on its oncology candidate, which has the potential to become the ...

Indaptus Therapeutics (INDP) announced a clinical supply agreement with BeiGene (BGNE). Building on Indaptus’ preclinical observation ...

Under Indaptus' clinical supply agreement with BeiGene, the New York biotechnology company plans to advance human clinical evaluation of its cancer treatment -- called Decoy20, which is being studied ...

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present at two upcoming investor ...

EMA committee recommends extended authorization for BeiGene’s Tevimbra to treat gastric or gastroesophageal junction cancer & ESCC: San Mateo, California Wednesday, October 23, ...

The positive evaluation from S&P affirms Fosun International's strong execution of its globalization and innovation capabilities. Over the past two years, the remarkable improvement in its balance ...

After hours: October 22 at 7:53 PM EDT ...

BriaCell Therapeutics could access a $1-$5 billion market upon approval despite a sub-$30 million cap. See more on BRIA stock ...

Therapeutic inhibition of NLRP3 can prevent the formation of the NLRP3 inflammasome, which in turn inhibits the production of pro-inflammatory cytokines like interleukin-1 beta and interleukin-18 ...